Carotid endarterectomy

Study Published in JAMA Finds Hospital Availability of TCAR Associated with an Improvement in Overall Outcomes for Carotid Revascularization

The study found the availability of TCAR at a hospital was associated with a significant decrease in the likelihood of major adverse cardiovascular events (MACE), a composite of in-hospital stroke, myocardial infarction, or death at 30 days after carotid revascularization, whether TCAR or carotid endarterectomy (CEA).

Key Points: 
  • The study found the availability of TCAR at a hospital was associated with a significant decrease in the likelihood of major adverse cardiovascular events (MACE), a composite of in-hospital stroke, myocardial infarction, or death at 30 days after carotid revascularization, whether TCAR or carotid endarterectomy (CEA).
  • We believe this indicates that centers that offer TCAR are able to better align patients with the best procedure for their individual clinical and anatomic characteristics.
  • The ENROUTE Transcarotid Stent is intended to be used in conjunction with the ENROUTE Transcarotid Neuroprotection System (NPS) during the TCAR procedure.
  • The companys flagship procedure, TransCarotid Artery Revascularization (TCAR), is clinically proven to treat blockages in the carotid artery at risk of causing a stroke.

InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States

Retrieved on: 
Wednesday, February 24, 2021

TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct the clinical trial for its CGuard Carotid Stent System in the United States.

Key Points: 
  • TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct the clinical trial for its CGuard Carotid Stent System in the United States.
  • HCC is ideally suited to manage this trial having supported clinical trial operations for a variety of products and indications, including with multiple carotid intervention procedures, stated Marvin Slosman, InspireMDs CEO.
  • This will be the first U.S.-based study of CGuard and our opportunity to demonstrate its potential for the prevention of stroke caused by carotid artery disease in patients in the United States.
  • We look forward to working with InspireMD on this pivotal trial of the CGuard System to help establish a new standard of care for the management of carotid artery disease and stroke prevention.

The Cardiovascular Care Group Leading the Way with New Innovative TCAR Procedure to Treat Carotid Artery Disease

Retrieved on: 
Wednesday, October 28, 2020

SCOTCH PLAINS, N.J., Oct. 28, 2020 /PRNewswire-PRWeb/ -- The Cardiovascular Care Group, in 2017, was the first group in New Jersey to treat carotid artery disease using a new procedure called TransCarotid Artery Revascularization (TCAR).

Key Points: 
  • SCOTCH PLAINS, N.J., Oct. 28, 2020 /PRNewswire-PRWeb/ -- The Cardiovascular Care Group, in 2017, was the first group in New Jersey to treat carotid artery disease using a new procedure called TransCarotid Artery Revascularization (TCAR).
  • TCAR is a clinically proven, minimally invasive and safe approach for high-risk patients who require carotid artery treatment.
  • Carotid artery disease is a form of atherosclerosis, or a buildup of plaque, in the main arteries in the neck that supply oxygen-rich blood to the brain.
  • Prior to TCAR, the main treatment option for severe carotid artery disease was an open surgical procedure called carotid endarterectomy (CEA).

AngioSoma Focusing on Development of Coating for Metal Stents

Retrieved on: 
Wednesday, May 27, 2020

Houston, TX, May 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma, Inc. ( OTC : SOAN)(AngioSoma or the Company) is pleased to announce that the Company is focusing on development and commercialization of our coating for metal stents.

Key Points: 
  • Houston, TX, May 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma, Inc. ( OTC : SOAN)(AngioSoma or the Company) is pleased to announce that the Company is focusing on development and commercialization of our coating for metal stents.
  • Our coating is a biodegradable, resorbable and hemocompatible surface substrate coating for metal stents to provide embolic protection in stenting procedures.
  • We believe our coating for stents has increased potential over and above what is on the market now to block restenosis (recurrence of narrowing).
  • We consider the addressable market for stents includes not only carotid artery stenting patients but also individuals undergoing carotid endarterectomy.

Favorable Outcomes with TCAR vs. Carotid Endarterectomy in Patients with Carotid Artery Disease

Additionally, TCAR patients experience shorter length of hospital stay and are discharged home more often, said Dr. Malas.

Key Points: 
  • Additionally, TCAR patients experience shorter length of hospital stay and are discharged home more often, said Dr. Malas.
  • I am confident that as this compelling clinical evidence continues to mount, TCAR will continue to challenge CEA as the standard of care for treating carotid artery disease in high surgical risk patients.
  • The updated data from the TCAR Surveillance Project evaluated patients between 2016 and 2019, with 8,104 patients receiving TCAR compared to 53,869 patients receiving carotid endarterectomy (CEA), with 6,526 patients in each group analyzed using propensity score matching.
  • The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR).

Global Carotid Artery Stenosis Therapeutics Market - Forecast and Analysis 2019-2023 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 10, 2019

Global Carotid Artery Stenosis Therapeutics Market: About this market

Key Points: 
  • Global Carotid Artery Stenosis Therapeutics Market: About this market
    The carotid artery stenosis therapeutics market analysis considers sales from antithrombotics, antihyperlipidemic, and antihypertensives products.
  • Also, our global carotid artery stenosis therapeutics market report looks at factors such as the increasing risk factors for carotid artery stenosis, increasing geriatric population, and growing awareness about carotid artery stenosis.
  • Global Carotid Artery Stenosis Therapeutics Market: Overview
    The growing awareness about carotid artery stenosis is important for its prevention, as delay in the diagnosis of this disease can be life-threatening.
  • The demand for carotid artery stenosis therapeutics is increasing with the growing awareness about stroke management and carotid artery stenosis through multiple educational programs initiated by government organizations.

Global Vascular Patch Market by Material, Application and Geography (2018-2023) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 29, 2019

The "Vascular Patch Market - Segmented by Material (Biologic, Synthetic), Application (Carotid Endarterectomy, Open Repair of Abdominal Aortic Aneurysms, Cardiac Aneurysm, Vascular Bypass Surgery) and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vascular Patch Market - Segmented by Material (Biologic, Synthetic), Application (Carotid Endarterectomy, Open Repair of Abdominal Aortic Aneurysms, Cardiac Aneurysm, Vascular Bypass Surgery) and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.
  • The vascular patch market is expected to grow at a CAGR of 8.4% over the forecast period.
  • Rapidly growing geriatric population and the subsequent increase in the prevalence of vascular diseases along with increasing adoption of biological patches is driving the market growth.
  • However, the high cost associated with the surgical procedure, changing reimbursement environment and recent product failures and recalls can retard the market growth.

Global Vascular Patches Market Report 2018-2023 - Opportunities in Emerging Markets

Retrieved on: 
Wednesday, July 4, 2018

The "Vascular Patches Market by Material, Application, Patient Care Setting - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vascular Patches Market by Material, Application, Patient Care Setting - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
  • The global vascular patches market is segmented into material, application, end user, and region.
  • Based on application, the vascular patches market is segmented into carotid endarterectomy, open repair of abdominal aortic aneurysms, vascular bypass surgery, and other applications.
  • Based on material, the vascular patches market has been segmented into biologic vascular patch and synthetic vascular patch.